OPDIVO 10 mg/ml solution for injection 10 mg/ml Solution for injection 4ml Vial
Product Overview
OPDIVO (Nivolumab) 10 mg/ml solution for injection is an advanced immunotherapy medication designed to harness the body's immune system to fight various types of cancer. This prescription-only medicine, manufactured by Bristol-Myers Squibb, is a Programmed Death-1 (PD-1) blocking antibody, crucial in treating malignancies like melanoma, non-small cell lung cancer, renal cell carcinoma, and classical Hodgkin lymphoma. Each 4ml vial contains 40mg of Nivolumab, formulated for intravenous administration by healthcare professionals.
Benefits of Use
- Activates the body's immune system to target and destroy cancer cells.
- Demonstrated to improve overall survival rates in various advanced cancers.
- Offers a targeted approach, potentially reducing side effects compared to traditional chemotherapy in some cases.
- Approved for a wide range of indications, providing therapeutic options for multiple cancer types.
How to Use
- OPDIVO is administered intravenously by a qualified healthcare professional in a clinical setting.
- The dosage and frequency of administration will be determined by your doctor based on your specific cancer type, stage, weight, and overall health.
- Ensure you attend all scheduled appointments for infusion.
- Report any side effects or concerns to your healthcare team immediately during or after treatment.
- Do not attempt to self-administer OPDIVO.
Caution & Warnings
- Immunotherapy can cause immune-mediated adverse reactions affecting any organ system. These can be severe or fatal.
- Common severe immune-mediated adverse reactions include pneumonitis, colitis, hepatitis, endocrinopathies (e.g., thyroid disorders, adrenal insufficiency), nephritis, and skin reactions.
- Infusion-related reactions may occur, requiring immediate medical attention.
- OPDIVO can cause harm to a fetus. Females of reproductive potential should use effective contraception during treatment and for 5 months after the last dose.
- Lactating mothers should avoid breastfeeding during treatment and for 5 months after the last dose.
- Patients should be closely monitored for signs and symptoms of adverse reactions throughout treatment and after discontinuation.
- Inform your doctor about all medical conditions, especially autoimmune diseases, organ transplant history, or previous immune-related side effects from other medications.
Ingredients
Active Ingredient:
- Nivolumab 10 mg/ml
Inactive Ingredients:
- Mannitol
- Pentetic acid
- Polysorbate 80
- Sodium chloride
- Sodium citrate dihydrate
- Hydrochloric acid (for pH adjustment)
- Sodium hydroxide (for pH adjustment)
- Water for injection
Product Details
Brand: OPDIVO
Scientific Name: Nivolumab
Strength: 10 mg/ml
Form: Solution for injection
Package Size: 4ml Vial
Manufacturer: Bristol-Myers Squibb (BMS)
Drug Type: Prescription Only Medicine (POM)
Storage: Store in a refrigerator (2°C to 8°C). Protect from light. Do not freeze.
| Gtin | 00319810901088 |
|---|---|
| Recommended Sale Price | 3385.15 |
| Is Wasfaty Product | No |
| Brand | Not Defined |
| Ingredient Name | NIVOLUMAB |
| SFDA Reg. No | 2-960-15 |
| IBC | 00319810901088 |
| Drug Type | Prescription |
| Scientific Name | Nivolumab |
| Strength | 10 |
| Strength Unit | mg/ml |
| Form | Solution for injection |
| Admin Route | Intravenous |
| Size | 4 |
| Size Unit | ml |
| Package Types | Vial |
| Package Size | 4ml |
| shelfLife | 24 months |
| Storage conditions | Store in a refrigerator at 2°C to 8°C. Protect from light. Do not freeze. |
| Refrigerator Storage | Yes |
